Alphatec (NASDAQ:ATEC) Trading Down 6.2% – What’s Next?

Posted by Francis Steltz on Jul 16th, 2026

Alphatec Holdings, Inc. (NASDAQ:ATEC – Get Free Report)’s share price dropped 6.2% during trading on Tuesday . The company traded as low as $8.88 and last traded at $9.1350. Approximately 288,484 shares changed hands during mid-day trading, a decline of 91% from the average session volume of 3,232,806 shares. The stock had previously closed at $9.74.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. TD Cowen decreased their target price on Alphatec from $20.00 to $11.00 and set a “buy” rating for the company in a report on Wednesday, May 6th. Wells Fargo & Company decreased their price objective on shares of Alphatec from $28.00 to $14.00 and set an “overweight” rating for the company in a research note on Thursday, May 7th. Barclays cut their target price on shares of Alphatec from $27.00 to $24.00 and set an “overweight” rating on the stock in a research note on Thursday, May 7th. Canaccord Genuity Group reduced their target price on shares of Alphatec from $25.00 to $23.00 and set a “buy” rating on the stock in a report on Wednesday, May 6th. Finally, JPMorgan Chase & Co. decreased their price target on shares of Alphatec from $24.00 to $16.00 and set an “overweight” rating for the company in a research report on Wednesday, May 6th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $17.46.

Read Our Latest Stock Analysis on ATEC

Alphatec Trading Up 0.8%

The business’s 50-day moving average price is $8.38 and its 200 day moving average price is $11.95. The company has a debt-to-equity ratio of 40.35, a current ratio of 1.90 and a quick ratio of 1.12. The firm has a market capitalization of $1.39 billion, a price-to-earnings ratio of -11.02 and a beta of 0.85.

Insiders Place Their Bets

In other Alphatec news, Director Karen K. Mcginnis sold 6,050 shares of the company’s stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $8.01, for a total value of $48,460.50. Following the completion of the transaction, the director directly owned 94,671 shares of the company’s stock, valued at $758,314.71. This represents a 6.01% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 13.48% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Alphatec

A number of institutional investors have recently made changes to their positions in ATEC. Handelsbanken Fonder AB purchased a new position in shares of Alphatec during the 2nd quarter valued at approximately $427,000. Redhawk Wealth Advisors Inc. increased its stake in shares of Alphatec by 87.8% in the second quarter. Redhawk Wealth Advisors Inc. now owns 19,412 shares of the medical technology company’s stock worth $168,000 after buying an additional 9,077 shares during the last quarter. Atlas Brown Inc. bought a new stake in shares of Alphatec in the second quarter worth $111,000. Valeo Financial Advisors LLC raised its holdings in Alphatec by 7.2% in the second quarter. Valeo Financial Advisors LLC now owns 44,363 shares of the medical technology company’s stock valued at $384,000 after acquiring an additional 2,967 shares in the last quarter. Finally, Western Wealth Management LLC boosted its stake in Alphatec by 20.9% during the 1st quarter. Western Wealth Management LLC now owns 103,909 shares of the medical technology company’s stock valued at $1,131,000 after acquiring an additional 17,928 shares during the last quarter. 66.35% of the stock is owned by institutional investors and hedge funds.

Alphatec Company Profile

(Get Free Report)

Alphatec Holdings, Inc (NASDAQ: ATEC) is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company’s portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec’s flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.

Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market.